MODIFIED HUMAN ERYTHROPOIETIN

A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KRATJE, Ricardo, APARICIO, Gabriela I, ETCHEVERRIGARAY, Marina, SCORTICATI, Camila, BURGI-FISSOLO, Maria de los Milagros, DORELLA, Aquiles, OGGERO-EBERHARDT, Marcos
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.